Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Inclusion Criteria: - Type 2 diabetes - Age min. 50 years at screening and concomitant
cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or
chronic heart failure OR age min. 60 years at screening and other specified risk factors of
cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with
one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or
long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s)
Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor
agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4
(DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin
other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3
months prior to screening. Short-term use of other insulin during this period in connection
with intercurrent illness is allowed, at Investigator's discretion